Open AccessProphylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice
Author(s) -
Jonathan P. Wong,
Edward G. Saravolac,
D Sabuda,
Hilton B. Levy,
Meir Kende
Publication year - 1995
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.39.11.2574
Subject(s) - virus , nasal administration , titer , virology , hemagglutination assay , respiratory system , influenza a virus , orthomyxoviridae , medicine , hemagglutination , immunology , biology , pharmacology , microbiology and biotechnology
Polyriboinosinic-polyribocytidylic acid [poly(IC.LC)] was evaluated for its prophylactic and therapeutic efficacies against respiratory influenza A virus infection in mice. Two doses of poly(IC.LC) (1 mg/kg of body weight per dose) administered intranasally within 12 days prior to infection with 10 50% lethal doses of mouse-adapted influenza A/PR/8 virus fully protected the mice against the infection. Determination of virus titers by hemagglutination and plaque assays showed more than a 2-log10 decrease in virus titers in lung homogenates of pretreated mice compared with those in the lungs of the nonpretreated group. Treatment of infected mice with poly(IC.LC) resulted in a modest (40%) survival rate. These results suggest that poly(IC.LC) provides a highly effective prophylaxis against respiratory influenza A virus infection in mice.